Abstract
There is growing evidence that Rho-kinase contributes to cardiovascular disease, which has made Rho-kinase a target for the treatment of human diseases. To date, the only Rho-kinase inhibitor employed clinically in humans is fasudil, which has been used for the prevention of cerebral vasospasm and subsequent ischemic injury after surgery for subarachnoid hemorrhage (SAH). A number of pathological processes, in particular hemodynamic dysfunctions and inflammatory reactions, are thought to be related in the pathogenesis of delayed cerebral vasospasm and subsequent ischemic injury after SAH. This review focuses on fasudil’s pleiotropic therapeutic effects: amelioration of hemodynamic dysfunction and inflammation, and discusses in detail the clinical studies on fasudil administered after the occurrence of SAH.
Keywords: Cerebral vasospasm, fasudil, hydroxyfasudil, pleiotropic therapeutic effects, Rho-kinase, subarachnoid hemorrhage.
Current Vascular Pharmacology
Title:Pleiotropic Effects of the Rho-kinase Inhibitor Fasudil After Subarachnoid Hemorrhage: A Review of Preclinical and Clinical Studies
Volume: 12 Issue: 5
Author(s): Shin-ichi Satoh, Ichiro Ikegaki, Koh Kawasaki, Toshio Asano and Masato Shibuya
Affiliation:
Keywords: Cerebral vasospasm, fasudil, hydroxyfasudil, pleiotropic therapeutic effects, Rho-kinase, subarachnoid hemorrhage.
Abstract: There is growing evidence that Rho-kinase contributes to cardiovascular disease, which has made Rho-kinase a target for the treatment of human diseases. To date, the only Rho-kinase inhibitor employed clinically in humans is fasudil, which has been used for the prevention of cerebral vasospasm and subsequent ischemic injury after surgery for subarachnoid hemorrhage (SAH). A number of pathological processes, in particular hemodynamic dysfunctions and inflammatory reactions, are thought to be related in the pathogenesis of delayed cerebral vasospasm and subsequent ischemic injury after SAH. This review focuses on fasudil’s pleiotropic therapeutic effects: amelioration of hemodynamic dysfunction and inflammation, and discusses in detail the clinical studies on fasudil administered after the occurrence of SAH.
Export Options
About this article
Cite this article as:
Satoh Shin-ichi, Ikegaki Ichiro, Kawasaki Koh, Asano Toshio and Shibuya Masato, Pleiotropic Effects of the Rho-kinase Inhibitor Fasudil After Subarachnoid Hemorrhage: A Review of Preclinical and Clinical Studies, Current Vascular Pharmacology 2014; 12 (5) . https://dx.doi.org/10.2174/1570161112666140613115813
DOI https://dx.doi.org/10.2174/1570161112666140613115813 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact of Tracer Retention Levels on Visual Analysis of Cerebral [<sup>18</sup>F]- Florbetaben Pet Images
Current Radiopharmaceuticals Arterial Dilatation-Related Diseases: The Prerequisite Condition of Arterial Elastic Tissue Damage and Endovascular Treatment
Recent Patents on Medical Imaging Hypopituitarism in Neurocritical Patients: A Case Report
Endocrine, Metabolic & Immune Disorders - Drug Targets Encountering and Advancing Through Antiangiogenesis Therapy for Gliomas
Current Pharmaceutical Design Role of Endothelial Progenitor Cell Mobilization After Percutaneous Angioplasty Procedure
Current Pharmaceutical Design How Should Serum Uric Acid Concentrations be Interpreted in Patients with Hypertension?
Current Hypertension Reviews Re: ‘Re. Renal Function Impairment in Patients Undergoing Elective EVAR vs Elective Open Repair During Follow up Period: A Systematic Review of the Literature’
Current Vascular Pharmacology Stroke after Thoracic Endovascular Aortic Aneurysm Repair: A Silent Enemy that Needs More Caution
Current Pharmaceutical Design Diagnosis of Surgically-Treatable Forms of Primary Aldosteronism
Current Hypertension Reviews Recreational Drug Misuse and Stroke
Current Drug Abuse Reviews Safety of Drug Eluting Stents: Current Concerns and Controversies
Current Drug Safety Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets Atherogenesis in Renal Patients: A Model of Vascular Disease?
Current Vascular Pharmacology Current Management of Traumatic Rupture of the Descending Thoracic Aorta
Current Cardiology Reviews Genetic Variability of Matrix Metalloproteinase Genes in Cardiovascular Disease
Current Topics in Medicinal Chemistry Clinical Approach for the Treatment of Obesity-associated Diseases
Current Pharmaceutical Design Emerging Pharmacological Treatments to Prevent Abdominal Aortic Aneurysm Growth and Rupture
Current Pharmaceutical Design Patent Selections:
Recent Patents on Anti-Infective Drug Discovery Update on the Imaging Techniques in the Diagnosis of Diabetic Retinopathy
Current Diabetes Reviews Mast Cells in Abdominal Aortic Aneurysms
Current Vascular Pharmacology